Role of contemporary pathological diagnostics in the personalized treatment of cancer;A patológiai diagnosztika jelentõsége a daganatos betegségek személyre szabott orvoslásában

Magyar Onkologia

Volumn 57, Issue 1, 2013, Pages 26-32

  József, Tímár ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cancer pathology; Molecular classification; Personalized medicine

Indexed keywords

MOLECULAR MARKER; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER PATIENT; DECISION MAKING; HUMAN; MOLECULAR DIAGNOSTICS; PERSONALIZED MEDICINE; ADENOCARCINOMA; ALGORITHM; BREAST TUMOR; CHEMISTRY; CLASSIFICATION; COLORECTAL TUMOR; DIFFERENTIAL DIAGNOSIS; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG TUMOR; MELANOMA; METHODOLOGY; MOLECULAR PATHOLOGY; MUTATION; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; SKIN TUMOR; THYROID TUMOR;

ADENOCARCINOMA; ALGORITHMS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MELANOMA; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; PATHOLOGY, MOLECULAR; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84879991380     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Tímár J, Fillinger J. Pathology of the lung cancer. Eur Respir Mon 48:1-25, 2010
2. Travis WD, Brambilla E, Noduchi M, et al. Diagnosis of lung adenocarcinoma in resected specimens. Implications of the 2011 International Association for the Study of the Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med 136:1-23, 2012
3. Rossi G, Pelosi G, Graziano P, et al. A reevaluation of the clinical significance of histological subtyping of non-small cell lung carcinoma: diagnostic algorithms in the era of personalized medicine. Int J Surg Pathol 17:2006-2018, 2009
4. Tímár J. A tüdörákok prognosztikus és prediktív patológiája. Med Thorac LXIV:74-85, 2011
5. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small cell lung cancers into routine clinical practice. Ann Oncol 22:2616-2624, 2011
6. Gold KA, Wistuba II, Kim ES. New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy. Clin Cancer Res 18:3002-3007, 2012
7. Rekhtman N, Oaik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker verified squamous carcinoma of the lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18:1167-1176, 2012
8. Peifer M, Fernandez-Cuesta L, Sos M, et al. Integrative genome analysis identify key somatic driver mutations of small cell lung cancer. Nat Genet 44:1104-1112, 2012
9. Pusztai L, Mazouni C, Anderson K, et al. Molecular classification of breast cancer: limitations and potential. Oncologist 11:868-877, 2006 (Pubitemid 44373759)
10. Oonk AM, van Rijn C, Smits MM, et al. Clinical correlates of BRCAness in triple negative breast cancer of patients receiving adjuvant chemotherapy. Ann Oncol 23:2301-2305, 2012
11. Martin M, Romero A, Cheang MC, et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 128:127-136, 2011
12. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490:61-69, 2012
13. Tian S, Roepman P, Popovici V, et al. A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. J Pathol 228:586-595, 2011
14. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
15. Yang Z-Y, Shen W-X, Hu X-F, et al. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-Analysis. J Hematol Oncol 5:52, 2012
16. Szentirmay Z, Gallai M, Serester O, et al. A microsatellita-státus és a morfológiai kép összefüggése vastagbélrákokban. Magyar Onkológia 54:169-178, 2010
17. Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation and adverse morphologic features. Am J Surg Pathol 36:744-752, 2012
18. Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB89803. Clin Cancer Res 18:890-900, 2012
19. Tímár J, Barbai T, Györffy B, Rásó E. Understanding melanoma progression by gene expression signatures. Chapter 2. Cancer Genomics, ed. Pfeffer U. Springer, Dordrecht, 2013 pp 47-78
20. Sosman JA, Kim KB, Schuchter L, et al. Survival of BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
21. Theoharis C, Roman S, Sosa JA. The molecular diagnosis and management of thyroid neoplasms. Curr Opin Oncol 24:35-41, 2012
22. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double blind phase 2 trial. Lancet Oncol 13:897-905, 2012
23. Bollag G, Tsai J, Zhang J, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11:873-886, 2012